{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:07:56Z","timestamp":1786997276904,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AA021908"],"award-info":[{"award-number":["R01 AA021908"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007904","name":"Texas A&M University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.taap.2017.11.024","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T01:36:53Z","timestamp":1512178613000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Effects of pirfenidone in acute and sub-chronic liver fibrosis, and an initiation-promotion cancer model in the mouse"],"prefix":"10.1016","volume":"339","author":[{"given":"Oleksii","family":"Seniutkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Syuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Cichocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisataka","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeki","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Rusyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2017.11.024_bb0005","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/labinvest.2016.36","article-title":"Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts","volume":"96","author":"Aoudjehane","year":"2016","journal-title":"Lab. Investig."},{"key":"10.1016\/j.taap.2017.11.024_bb0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.taap.2017.11.024_bb0015","doi-asserted-by":"crossref","first-page":"F676","DOI":"10.1152\/ajprenal.00507.2012","article-title":"Pirfenidone inhibits macrophage infiltration in 5\/6 nephrectomized rats","volume":"304","author":"Chen","year":"2013","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.taap.2017.11.024_bb0020","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.dld.2004.05.012","article-title":"The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2","volume":"36","author":"Di Sario","year":"2004","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.taap.2017.11.024_bb0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-230X-14-131","article-title":"Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C","volume":"14","author":"Flores-Contreras","year":"2014","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.taap.2017.11.024_bb0030","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0168-8278(02)00272-6","article-title":"Pirfenidone effectively reverses experimental liver fibrosis","volume":"37","author":"Garcia","year":"2002","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2017.11.024_bb0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/01926230252824770","article-title":"Quantitation of the cancer process in C57BL\/6J, B6C3F1 and C3H\/HeJ mice","volume":"30","author":"Goldsworthy","year":"2002","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.taap.2017.11.024_bb0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1465-9921-15-16","article-title":"Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis","volume":"15","author":"Inomata","year":"2014","journal-title":"Respir. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.taap.2017.11.024_bb0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1440-1746.2011.07002.x","article-title":"What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis","volume":"27","author":"Iwaisako","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.taap.2017.11.024_bb0050","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1023\/A:1007068313370","article-title":"Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation","volume":"24","author":"Iyer","year":"2000","journal-title":"Inflammation"},{"key":"10.1016\/j.taap.2017.11.024_bb0055","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-015-0350-9","article-title":"Pirfenidone: a review of its use in idiopathic pulmonary fibrosis","volume":"75","author":"Kim","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.taap.2017.11.024_bb0060","doi-asserted-by":"crossref","first-page":"44754","DOI":"10.1038\/srep44754","article-title":"Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis","volume":"7","author":"Komiya","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2017.11.024_bb0065","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2008.01.026","article-title":"Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis","volume":"48","author":"Lackner","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2017.11.024_bb0070","doi-asserted-by":"crossref","first-page":"e000079","DOI":"10.1136\/bmjgast-2016-000079","article-title":"Hepatic macrophages in liver fibrosis: pathogenesis and potential therapeutic targets","volume":"3","author":"Li","year":"2016","journal-title":"BMJ Open Gastroenterol."},{"key":"10.1016\/j.taap.2017.11.024_bb0075","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7150\/ijms.11579","article-title":"Role and new insights of pirfenidone in fibrotic diseases","volume":"12","author":"Lopez-de la Mora","year":"2015","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.taap.2017.11.024_bb0080","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/s-0035-1550055","article-title":"Antifibrotic therapies in the liver","volume":"35","author":"Mehal","year":"2015","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.taap.2017.11.024_bb0085","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","article-title":"Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis","volume":"590","author":"Oku","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.taap.2017.11.024_bb0090","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.bbadis.2012.12.007","article-title":"Strategies for anti-fibrotic therapies","volume":"1832","author":"Rosenbloom","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.taap.2017.11.024_bb0095","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejphar.2008.06.110","article-title":"Potent antioxidant role of pirfenidone in experimental cirrhosis","volume":"595","author":"Salazar-Montes","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.taap.2017.11.024_bb0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic activities of pirfenidone in animal models","volume":"20","author":"Schaefer","year":"2011","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.taap.2017.11.024_bb0105","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.taap.2017.11.024_bb0110","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.taap.2017.11.024_bb0115","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.27332","article-title":"Hepatic inflammation and fibrosis: functional links and key pathways","volume":"61","author":"Seki","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2017.11.024_bb0120","series-title":"Report on Pirfenidone 200mg","author":"Shionogi & Co.","year":"2008"},{"key":"10.1016\/j.taap.2017.11.024_bb0125","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1440-1681.2001.03481.x","article-title":"Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats","volume":"28","author":"Tada","year":"2001","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.taap.2017.11.024_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/toxsci\/kfs342","article-title":"Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis","volume":"132","author":"Uehara","year":"2013","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.taap.2017.11.024_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/0471141755.ph1430s66","article-title":"The DEN and CCl4 -induced mouse model of fibrosis and inflammation-associated hepatocellular carcinoma","volume":"66","author":"Uehara","year":"2014","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.taap.2017.11.024_bb0140","doi-asserted-by":"crossref","first-page":"e95462","DOI":"10.1371\/journal.pone.0095462","article-title":"The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices","volume":"9","author":"Westra","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2017.11.024_bb0145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tiv.2016.05.012","article-title":"Human precision-cut liver slices as a model to test antifibrotic drugs in the early onset of liver fibrosis","volume":"35","author":"Westra","year":"2016","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.taap.2017.11.024_bb0150","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","article-title":"Macrophages in tissue repair, regeneration, and fibrosis","volume":"44","author":"Wynn","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.taap.2017.11.024_bb0155","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3892\/mmr.2015.3403","article-title":"Pirfenidone inhibits proliferation, arrests the cell cycle, and downregulates heat shock protein-47 and collagen type I in rat hepatic stellate cells in vitro","volume":"12","author":"Xiang","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.taap.2017.11.024_bb0160","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12931-016-0418-4","article-title":"Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis","volume":"17","author":"Xie","year":"2016","journal-title":"Respir. Res."},{"key":"10.1016\/j.taap.2017.11.024_bb0165","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1440-1681.2009.05194.x","article-title":"Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells","volume":"36","author":"Zhao","year":"2009","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.taap.2017.11.024_bb0170","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00003088-199019020-00004","article-title":"Disease-induced variations in plasma protein levels. Implications for drug dosage regimens part I","volume":"19","author":"Zini","year":"1990","journal-title":"Clin. Pharmacokinet."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X17304696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X17304696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T04:37:02Z","timestamp":1575520622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X17304696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":34,"alternative-id":["S0041008X17304696"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2017.11.024","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of pirfenidone in acute and sub-chronic liver fibrosis, and an initiation-promotion cancer model in the mouse","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2017.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}